NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$275.1m

Last Updated

2021/05/07 22:41 UTC

Data Sources

Company Financials +

Executive Summary

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. More Details


Snowflake Analysis

Excellent balance sheet and fair value.


Similar Companies

Share Price & News

How has EyePoint Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EYPT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: EYPT's weekly volatility (12%) has been stable over the past year.


Market Performance


7 Day Return

-8.9%

EYPT

2.7%

US Pharmaceuticals

-0.3%

US Market


1 Year Return

12.3%

EYPT

12.1%

US Pharmaceuticals

50.2%

US Market

Return vs Industry: EYPT matched the US Pharmaceuticals industry which returned 11.4% over the past year.

Return vs Market: EYPT underperformed the US Market which returned 51.8% over the past year.


Shareholder returns

EYPTIndustryMarket
7 Day-8.9%2.7%-0.3%
30 Day-8.8%3.8%2.2%
90 Day-30.3%1.4%3.8%
1 Year12.3%12.3%16.0%12.1%52.7%50.2%
3 Year-51.5%-51.5%34.5%24.1%63.4%53.1%
5 Year-64.6%-64.6%49.0%30.6%129.6%104.0%

Long-Term Price Volatility Vs. Market

How volatile is EyePoint Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is EyePoint Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: EYPT ($9.74) is trading below our estimate of fair value ($25.42)

Significantly Below Fair Value: EYPT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: EYPT is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: EYPT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EYPT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EYPT is good value based on its PB Ratio (2.1x) compared to the US Pharmaceuticals industry average (3.6x).


Future Growth

How is EyePoint Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

44.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EYPT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EYPT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EYPT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EYPT's revenue (30.5% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: EYPT's revenue (30.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if EYPT's Return on Equity is forecast to be high in 3 years time


Past Performance

How has EyePoint Pharmaceuticals performed over the past 5 years?

-20.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EYPT is currently unprofitable.

Growing Profit Margin: EYPT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EYPT is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.

Accelerating Growth: Unable to compare EYPT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EYPT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.6%).


Return on Equity

High ROE: EYPT has a negative Return on Equity (-38.46%), as it is currently unprofitable.


Financial Health

How is EyePoint Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: EYPT's short term assets ($159.4M) exceed its short term liabilities ($13.4M).

Long Term Liabilities: EYPT's short term assets ($159.4M) exceed its long term liabilities ($58.0M).


Debt to Equity History and Analysis

Debt Level: EYPT's debt to equity ratio (32.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if EYPT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EYPT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: EYPT has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 32.6% each year.


Dividend

What is EyePoint Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EYPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EYPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EYPT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EYPT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EYPT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Nancy Lurker (63 yo)

4.67yrs

Tenure

US$2,079,783

Compensation

Ms. Nancy S. Lurker serves as an Member of Advisory Group at Novo Holdings A/S. She has been the Chief Executive Officer and President of EyePoint Pharmaceuticals, Inc. (formerly known as pSivida Corp.) si...


CEO Compensation Analysis

Compensation vs Market: Nancy's total compensation ($USD2.08M) is above average for companies of similar size in the US market ($USD993.61K).

Compensation vs Earnings: Nancy's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: EYPT's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: EYPT's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 130.4%.


Top Shareholders

Company Information

EyePoint Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: EyePoint Pharmaceuticals, Inc.
  • Ticker: EYPT
  • Exchange: NasdaqGM
  • Founded: 1987
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$275.056m
  • Shares outstanding: 28.74m
  • Website: https://eyepointpharma.com

Number of Employees


Location

  • EyePoint Pharmaceuticals, Inc.
  • 480 Pleasant Street
  • Suite B300
  • Watertown
  • Massachusetts
  • 2472
  • United States

Listings


Biography

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/07 22:41
End of Day Share Price2021/05/07 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.